Senate Aging Committee examines Alzheimer's in Washington
Rudolph Tanzi, Ph.D., testifies about Alzheimer's disease before the Senate Special Committee on Aging on Capitol Hill in Washington on May 14, 2008. Tanzi is director of Generics and Aging Research Unit, Mass. General Institute for Neurodegenerative Diseases and professor of neurology at Harvard University. (UPI Photo/Roger L. Wollenberg)
Latest Headlines
U.S. drug maker Eli Lilly and Co. said it stopped its Phase II study of a promising drug to slow Alzheimer's disease over concerns about potential liver damage.
Drugs used for hypertension or insomnia may also help reduce the development of amyloid plaques, which is linked to Alzheimer's, U.S. researchers say.
U.S. researchers say a system that lets people control a flying robot with their mind could help people who are paralyzed or have neurodegenerative diseases.
UPI Almanac for Wednesday, June 5, 2013.
Researchers at the University of Southern California found a class of pharmaceuticals they say can both prevent and treat Alzheimer's disease in mice.
British researchers say vitamins B6, B12 and folic acid lower levels of homocysteine, which may reduce Alzheimer's disease risk.
When the brain's primary "learning center" is damaged it can rewire itself, creating new neural circuits to compensate for lost functions, U.S. researchers say.
Former New York Jets star George Sauer died in Ohio this week at the age of 69, his sister said.
Families with exceptional longevity appear to have delayed onset of Alzheimer's disease, U.S. researchers say.
Baxter International Inc. officials said its Phase III clinical study of immunoglobulin did not reduce cognitive decline in those with moderate Alzheimer's.
